Molecule intelOpportunity: ModerateEssentialCrowded market

Escitalopram

230 brands · 179 companies · product forms

ATC: N06AB10

Opportunity snapshot

Launch attractiveness
35
Market saturation
100
Price room
100
Regulatory risk
0
230
brands
179
companies
Rs 543.84
median price
118
price points
24.09x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 2%

Price room

Across observed sources and strengths
CheapestRs 145.75
MedianRs 543.84
Most expensiveRs 3,511.65
Spread24.09×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 24.09x across 118 trusted points (Rs 145.75-3511.65). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Escitalopram — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

179 canonical companies and 230 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 24.09x across 118 trusted points (Rs 145.75-3511.65). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.